Key facts
as of Sep 2026- Umoja Biopharma’s last known valuation is $420.0M (Jan 2025).
- It has raised $371.0M across 1 recorded rounds; the latest was Later Stage VC ($210.0M) in Jun 2021.
- Notable investors include SoftBank Investment Advisers, Qiming Venture Partners USA, Temasek Holdings, Realm Capital Ventures, Alexandria Venture Investments — 25 tracked in total.
- 1 institutional filer reports fund marks on Umoja Biopharma across 5 filings.
- Umoja Biopharma has filed 1 Form D with the SEC, most recently Jun 2021 ($210.0M sold to 29 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Umoja Biopharma
Recorded secondary trades
No secondary trades in Umoja Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest Apr 20261 SEC-registered fund reported 5 fair-value marks on Umoja Biopharma between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout Umoja Biopharma
Operator of a biotechnology platform designed to advance a novel approach to cancer immunotherapy by generating engineered immune cells. The company's platform offers integrated gene delivery technology, in-house lentiviral vector development, and a pipeline of in vivo cell therapies, enabling clinical researchers to pursue treatments that may reach more patients with improved accessibility and immune system-based control compared to conventional methods.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2019
- Employees
- 195
- Website
- umoja-biopharma.com/
- Ownership
- Privately Held (backing)